EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment

Alexander Foss, Tryfon Rotsos, Theo Empeslidis, Victor Chong

Ophthalmologica · 2022 · 245 (3) · 204-217

DOI: 10.1159/000520171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ophthalmologica, online erschienen am 25.10.2021. Verfasst von Alexander Foss und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Nottingham Medical School, Queen's Medical Centre, Nottingham, United Kingdom. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Wet Macular Degeneration. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age-related macular degeneration (AMD) is a leading cause of blindness. Late AMD can be classified into exudative (commonly known as wet AMD [wAMD]) or dry AMD, both of which may progress to macular atrophy (MA). MA causes irreversible vision loss and currently has no approved pharmacological treatment. The standard of care for wAMD is treatment with anti-vascular endothelial growth factors (VEGFs). However, recent evidence suggests that anti-VEGF treatment may play a role in the development of MA. Therefore, it is important to identify risk factors for the development of MA in patients with wAMD. For example, excessive blockade of VEGF through intense use of anti-VEGF agents may accelerate the development of MA. Patients with type III macular neovascularization (retinal angiomatous proliferation) have a particularly high risk of MA. These patients are characterized as having a pre-existing thin choroid (age-related choroidopathy), suggesting that the choroidal circulation is unable to respond to increased VEGF expression. Evidence suggests that subretinal fluid (possibly indicative of residual VEGF activity) may play a protective role. Patients receiving anti-VEGF agents must be assessed for overall risk of MA, and there is an unmet medical need to prevent the development of MA without undertreating wAMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationWet Macular DegenerationAngiogenesis InhibitorsAtrophyHumansIntravitreal InjectionsVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Stichwörter der Autor:innen

Age-related macular degenerationAnti-vascular endothelial growth factorsGeographic atrophyMacular atrophy

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Autor:innen und Institutionen

  • University of Nottingham Medical School, Queen's Medical Centre, Nottingham, United Kingdom.
  • Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.
  • Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.

Zitieren

APA

Foss, A., Rotsos, T., Empeslidis, T., & Chong, V. (2022). Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica, 245(3), 204-217. https://doi.org/10.1159/000520171

Vancouver

Foss A, Rotsos T, Empeslidis T, Chong V. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica. 2022;245(3):204-217. doi:10.1159/000520171

BibTeX
@article{Foss2022,
  author = {Foss, Alexander and Rotsos, Tryfon and Empeslidis, Theo and Chong, Victor},
  title = {Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment},
  journal = {Ophthalmologica},
  year = {2022},
  volume = {245},
  number = {3},
  pages = {204--217},
  doi = {10.1159/000520171}
}
Kostenlos starten →